Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study.
de Pauw BE, Sable CA, Walsh TJ, Lupinacci RJ, Bourque MR, Wise BA, Nguyen BY, DiNubile MJ, Teppler H. de Pauw BE, et al. Among authors: sable ca. Transpl Infect Dis. 2006 Mar;8(1):31-7. doi: 10.1111/j.1399-3062.2006.00127.x. Transpl Infect Dis. 2006. PMID: 16623818 Clinical Trial.
Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J; Caspofungin Invasive Candidiasis Study Group. Mora-Duarte J, et al. N Engl J Med. 2002 Dec 19;347(25):2020-9. doi: 10.1056/NEJMoa021585. N Engl J Med. 2002. PMID: 12490683 Free article. Clinical Trial.
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ; Caspofungin Salvage Aspergillosis Study Group. Maertens J, et al. Among authors: sable ca. Clin Infect Dis. 2004 Dec 1;39(11):1563-71. doi: 10.1086/423381. Epub 2004 Nov 9. Clin Infect Dis. 2004. PMID: 15578352 Clinical Trial.
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.
Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA. Walsh TJ, et al. Among authors: sable ca. Antimicrob Agents Chemother. 2005 Nov;49(11):4536-45. doi: 10.1128/AAC.49.11.4536-4545.2005. Antimicrob Agents Chemother. 2005. PMID: 16251293 Free PMC article.
Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
Hiemenz JW, Raad II, Maertens JA, Hachem RY, Saah AJ, Sable CA, Chodakewitz JA, Severino ME, Saddier P, Berman RS, Ryan DM, Dinubile MJ, Patterson TF, Denning DW, Walsh TJ. Hiemenz JW, et al. Among authors: sable ca. Eur J Clin Microbiol Infect Dis. 2010 Nov;29(11):1387-94. doi: 10.1007/s10096-010-1013-0. Epub 2010 Aug 12. Eur J Clin Microbiol Infect Dis. 2010. PMID: 20703506 Clinical Trial.
111 results